Compare Gilead Sciences, Inc. (GILD) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Gilead Sciences, Inc. trades at $133.05 (market cap $163.51B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $58.94. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while Vanguard Emerging Markets Stock Index Fund ETF pays none, and Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| GILD | VWO | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | — |
52-Week High | $155.80 | $61.24 |
52-Week Low | $108.22 | $49.54 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
VWO trades at $58.73, down 0.59% today, with a neutral technical signal and bullish moving averages. The ETF offers broad emerging markets exposure with a low 0.06% expense ratio and a 2.4% dividend yield, though key valuation metrics are unavailable. Recent news highlights strong capital inflows into emerging markets and competitive positioning against higher-fee peers like EEM.
Outlook is supported by diversification benefits and cost efficiency, but risks include China's economic volatility and geopolitical tensions. Analyst sentiment is mixed, focusing on expense advantages versus concentrated emerging market risks. The fund's performance hinges on global economic trends and regional stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
